查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1309269

毛細胞白血病市場：規模 - 按治療類型、療法、產品類型、藥物類別、給藥途徑、最終用戶、區域展望、競爭策略、到 2033 年的細分市場預測

Hairy Cell Leukemia Market Size- By Treatment Type, By Therapy Type, By Product Type, By Drug Class, By Route of Administration, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 250 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到2033年，全球毛細胞白血病市場規模將達到1億美元，年複合成長率為4.89%。

本報告考察了全球毛細胞白血病市場，並按治療類型、療法、產品類型、藥物類別、給藥途徑、最終用戶、地區和進入市場的參與者概況提供了市場概述以及趨勢。

目錄

第1章 簡介

第2章 調查方法

第3章 執行摘要

第4章 市場動態

  • 驅動因素、限制因素、機遇和挑戰分析
  • COVID-19 對全球毛細胞白血病市場的影響

第5章 市場變量與展望

  • SWOT分析
  • PESTEL分析
  • 波特五力
  • 熱圖分析

第6章 競爭格局

第7章 全球毛細胞白血病市場：按治療類型（百萬美元）

  • 2023-2033年全球毛細胞白血病市場價值佔有率及預測：按治療類型
  • 藥物治療
  • 外科手術

第8章 全球毛細胞白血病市場：按治療分類（百萬美元）

  • 2023-2033年全球毛細胞白血病市場價值佔有率及預測：按治療方法
  • 化學處理
  • 免疫療法
  • 靶向治療

第9章 全球毛細胞白血病市場：按產品類型（百萬美元）

  • 2023-2033年全球毛細胞白血病市場價值佔有率及預測：按產品類型
  • 膠囊
  • 腸外用藥
  • 藥片
  • 其他

第10章 全球毛細胞白血病市場：按藥物類別（百萬美元）

  • 2023-2033年全球毛細胞白血病市場價值佔有率及預測：按藥物類別
  • Belzutifan
  • Bevacizumab
  • Carmustine
  • Everolimus
  • Lomustine
  • Temozolomide
  • 其他

第11章 全球毛細胞白血病市場：按給藥途徑分類（百萬美元）

  • 2023-2033年全球毛細胞白血病市場價值佔有率及預測：按給藥途徑
  • 口服
  • 注射用
  • 其他

第12章 全球毛細胞白血病市場：按最終用戶分類（百萬美元）

  • 2023-2033年全球毛細胞白血病市場價值佔有率及預測：按最終用戶
  • 家庭護理
  • 醫院
  • 專科診所
  • 其他

第13章 2019-2033年全球毛細胞白血病市場預測（百萬美元）

第14章 全球毛細胞白血病市場：按治療類型，2019-2033（百萬美元）

第15章 全球毛細胞白血病市場：按治療方法，2019-2033年（百萬美元）

第16章 全球毛細胞白血病市場：按產品類型，2019-2033（百萬美元）

第17章 全球毛細胞白血病市場：按藥物類別，2019-2033（百萬美元）

第18章 全球毛細胞白血病市場：按給藥途徑分類，2019-2033年（百萬美元）

第19章 全球毛細胞白血病市場：按最終用戶分類，2019-2033年（百萬美元）

第20章 全球毛細胞白血病市場：按地區，2019-2033（百萬美元）

  • 全球毛細胞白血病市場規模及市場佔有率：按地區分類（2019-2026）
  • 全球毛細胞白血病市場規模及市場佔有率：按地區分類（2027-2033）
  • 亞太地區
  • 歐洲
  • 中東/非洲
  • 北美
  • 拉丁美洲

第二十一章 公司簡介

  • AbbVie Inc
  • Amgen Inc
  • Astellas Pharma Inc
  • Astex Therapeutics
  • AstraZeneca
  • Bayer AG
  • Biogenomics Limited
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company Limited
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Emcure Pharmaceuticals
  • Fresenius SE and Co. KGaA
  • GlaxoSmithKline plc
  • Hoffmann-La Roche
  • Janssen Global Services
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.
  • Sumitomo Dainippon Pharma Co.
  • Takeda Pharmaceutical Company Limited
  • 其他

第22章 縮寫表

第23章 參考鏈接

第24章 結論

第25章 調查範圍

簡介目錄
Product Code: HLCA2348

Hairy Cell Leukemia Market Overview

According to SPER market research, 'Hairy Cell Leukemia Market Size- By Treatment Type, By Therapy Type, By Product Type, By Drug Class, By Route of Administration, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Hairy Cell Leukemia Market is predicted to reach USD 0.10 billion by 2033 with a CAGR of 4.89%.

Hairy cell leukaemia is a rare type of cancer, in which the bone marrow causes lymphocytes to develop out of control. The name "hairy cell leukaemia" refers to a characteristic of the disease's morphology. In hairy cell leukaemia, the extra B cells grow aberrant extensions and have a hairy appearance. The quantity of healthy white blood cells, red blood cells, and platelets in the body decrease noticeably as the number of leukaemia cells increases. Usually, the illness takes time to develop without any noticeable symptoms.

Healthcare services were affected as a result of the COVID-19 pandemic, reducing access to basic care, including diagnosis and treatment. Delays in the clinical trials for the new treatments have an impact on therapy developments. Disruptions in the supply chain made it difficult to manage treatment plans and obtain the necessary drugs. There were fewer in-person visits and monitoring sessions, which increased reliance on online consultations. Challenges with affordability and reimbursement arose as a result of financial issues.

Scope of the Report:

Report Metric Details

Market size available for years 2019-2033

Base year considered 2022

Forecast period 2023-2033

Segments covered By Treatment Type, By Therapy Type, By Product Type, By Drug Class, By Route of Administration, By End User

Regions covered Asia-Pacific, Europe, the Middle East and Africa, North America, and Latin America

Companies Covered AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Astex Therapeutics, AstraZeneca, Bayer AG, Biogenomics Limited, Bristol Myers Squibb Company, Fresenius SE and Co. KGaA, GlaxoSmithKline plc, Hoffmann-La Roche, Janssen Global Services,

Hairy Cell Leukemia Market Key Segments Covered

By Therapy Type: Based on the Therapy Type, Global Hairy Cell Leukemia Market is segmented as; Chemotherapy, Immunotherapy, Targeted Therapy.

By Product Type: Based on the Product Type, Global Hairy Cell Leukemia Market is segmented as; Capsules, Parenterals, Tablets, Others.

By End User: Based on the Product Type, Global Hairy Cell Leukemia Market is segmented as; Homecare, Hospitals, Specialty Clinics, Others.

By Region: This research also includes data for Asia-Pacific, Europe, the Middle East and Africa, North America, and Latin America.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Hairy Cell Leukemia Market

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Hairy Cell Leukemia Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Hairy Cell Leukemia Market

7. Global Hairy Cell Leukemia Market, By Treatment Type (USD Million)

  • 7.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Treatment Type, 2023-2033
  • 7.2. Medication
  • 7.3. Surgery

8. Global Hairy Cell Leukemia Market, By Therapy Type (USD Million)

  • 8.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Therapy Type, 2023-2033
  • 8.2. Chemotherapy
  • 8.3. Immunotherapy
  • 8.4. Targeted Therapy

9. Global Hairy Cell Leukemia Market, By Product Type (USD Million)

  • 9.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Product Type, 2023-2033
  • 9.2. Capsules
  • 9.3. Parenterals
  • 9.4. Tablets
  • 9.5. Others

10. Global Hairy Cell Leukemia Market, By Drug Class (USD Million)

  • 10.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Drug Class, 2023-2033
  • 10.2. Belzutifan
  • 10.3. Bevacizumab
  • 10.4. Carmustine
  • 10.5. Everolimus
  • 10.6. Lomustine
  • 10.7. Temozolomide
  • 10.8. Others

11. Global Hairy Cell Leukemia Market, By Route of Administration (USD Million)

  • 11.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Route of Administration, 2023-2033
  • 11.2. Oral
  • 11.3. Parenteral
  • 11.4. Others

12. Global Hairy Cell Leukemia Market, By End User (USD Million)

  • 12.1. Global Hairy Cell Leukemia Market Value Share and Forecast, End User, 2023-2033
  • 12.2. Homecare
  • 12.3. Hospitals
  • 12.4. Specialty Clinics
  • 12.5. Others

13. Global Hairy Cell Leukemia Market Forecast, 2019-2033 (USD Million)

  • 13.1. Global Hairy Cell Leukemia Market Size and Market Share

14. Global Hairy Cell Leukemia Market, By Treatment Type, 2019-2033 (USD Million)

  • 14.1. Global Hairy Cell Leukemia Market Size and Market Share By Treatment Type (2019-2026)
  • 14.2. Global Hairy Cell Leukemia Market Size and Market Share By Treatment Type (2027-2033)

15. Global Hairy Cell Leukemia Market, By Therapy Type, 2019-2033 (USD Million)

  • 15.1. Global Hairy Cell Leukemia Market Size and Market Share By Therapy Type (2019-2026)
  • 15.2. Global Hairy Cell Leukemia Market Size and Market Share By Therapy Type (2027-2033)

16. Global Hairy Cell Leukemia Market, By Product Type, 2019-2033 (USD Million)

  • 16.1. Global Hairy Cell Leukemia Market Size and Market Share By Product Type (2019-2026)
  • 16.2. Global Hairy Cell Leukemia Market Size and Market Share By Product Type (2027-2033)

17. Global Hairy Cell Leukemia Market, By Drug Class, 2019-2033 (USD Million)

  • 17.1. Global Hairy Cell Leukemia Market Size and Market Share By Drug Class (2019-2026)
  • 17.2. Global Hairy Cell Leukemia Market Size and Market Share By Drug Class (2027-2033)

18. Global Hairy Cell Leukemia Market, By Route of Administration, 2019-2033 (USD Million)

  • 18.1. Global Hairy Cell Leukemia Market Size and Market Share By Route of Administration (2019-2026)
  • 18.2. Global Hairy Cell Leukemia Market Size and Market Share By Route of Administration (2027-2033)

19. Global Hairy Cell Leukemia Market, By End User, 2019-2033 (USD Million)

  • 19.1. Global Hairy Cell Leukemia Market Size and Market Share By End User (2019-2026)
  • 19.2. Global Hairy Cell Leukemia Market Size and Market Share By End User (2027-2033)

20. Global Hairy Cell Leukemia Market, By Region, 2019-2033 (USD Million)

  • 20.1. Global Hairy Cell Leukemia Market Size and Market Share By Region (2019-2026)
  • 20.2. Global Hairy Cell Leukemia Market Size and Market Share By Region (2027-2033)
  • 20.3. Asia-Pacific
    • 20.3.1. Australia
    • 20.3.2. China
    • 20.3.3. India
    • 20.3.4. Japan
    • 20.3.5. South Korea
    • 20.3.6. Rest of Asia-Pacific
  • 20.4. Europe
    • 20.4.1. France
    • 20.4.2. Germany
    • 20.4.3. Italy
    • 20.4.4. Spain
    • 20.4.5. United Kingdom
    • 20.4.6. Rest of Europe
  • 20.5. Middle East and Africa
    • 20.5.1. Kingdom of Saudi Arabia
    • 20.5.2. United Arab Emirates
    • 20.5.3. Rest of Middle East & Africa
  • 20.6. North America
    • 20.6.1. Canada
    • 20.6.2. Mexico
    • 20.6.3. United States
  • 20.7. Latin America
    • 20.7.1. Argentina
    • 20.7.2. Brazil
    • 20.7.3. Rest of Latin America

21. Company Profile

  • 21.1. AbbVie Inc,
    • 21.1.1. Company details
    • 21.1.2. Financial outlook
    • 21.1.3. Product summary
    • 21.1.4. Recent developments
  • 21.2. Amgen Inc
    • 21.2.1. Company details
    • 21.2.2. Financial outlook
    • 21.2.3. Product summary
    • 21.2.4. Recent developments
  • 21.3. Astellas Pharma Inc
    • 21.3.1. Company details
    • 21.3.2. Financial outlook
    • 21.3.3. Product summary
    • 21.3.4. Recent developments
  • 21.4. Astex Therapeutics
    • 21.4.1. Company details
    • 21.4.2. Financial outlook
    • 21.4.3. Product summary
    • 21.4.4. Recent developments
  • 21.5. AstraZeneca
    • 21.5.1. Company details
    • 21.5.2. Financial outlook
    • 21.5.3. Product summary
    • 21.5.4. Recent developments
  • 21.6. Bayer AG
    • 21.6.1. Company details
    • 21.6.2. Financial outlook
    • 21.6.3. Product summary
    • 21.6.4. Recent developments
  • 21.7. Biogenomics Limited
    • 21.7.1. Company details
    • 21.7.2. Financial outlook
    • 21.7.3. Product summary
    • 21.7.4. Recent developments
  • 21.8. Bristol Myers Squibb Company
    • 21.8.1. Company details
    • 21.8.2. Financial outlook
    • 21.8.3. Product summary
    • 21.8.4. Recent developments
  • 21.9. Celgene Corporation
    • 21.9.1. Company details
    • 21.9.2. Financial outlook
    • 21.9.3. Product summary
    • 21.9.4. Recent developments
  • 21.10. Daiichi Sankyo Company Limited
    • 21.10.1. Company details
    • 21.10.2. Financial outlook
    • 21.10.3. Product summary
    • 21.10.4. Recent developments
  • 21.11. Dr. Reddy's Laboratories Ltd
    • 21.11.1. Company details
    • 21.11.2. Financial outlook
    • 21.11.3. Product summary
    • 21.11.4. Recent developments
  • 21.12. Eli Lilly and Company
    • 21.12.1. Company details
    • 21.12.2. Financial outlook
    • 21.12.3. Product summary
    • 21.12.4. Recent developments
  • 21.13. Emcure Pharmaceuticals
    • 21.13.1. Company details
    • 21.13.2. Financial outlook
    • 21.13.3. Product summary
    • 21.13.4. Recent developments
  • 21.14. Fresenius SE and Co. KGaA
    • 21.14.1. Company details
    • 21.14.2. Financial outlook
    • 21.14.3. Product summary
    • 21.14.4. Recent developments
  • 21.15. GlaxoSmithKline plc
    • 21.15.1. Company details
    • 21.15.2. Financial outlook
    • 21.15.3. Product summary
    • 21.15.4. Recent developments
  • 21.16. Hoffmann-La Roche
    • 21.16.1. Company details
    • 21.16.2. Financial outlook
    • 21.16.3. Product summary
    • 21.16.4. Recent developments
  • 21.17. Janssen Global Services
    • 21.17.1. Company details
    • 21.17.2. Financial outlook
    • 21.17.3. Product summary
    • 21.17.4. Recent developments
  • 21.18. Johnson & Johnson Services, Inc.
    • 21.18.1. Company details
    • 21.18.2. Financial outlook
    • 21.18.3. Product summary
    • 21.18.4. Recent developments
  • 21.19. Merck & Co., Inc
    • 21.19.1. Company details
    • 21.19.2. Financial outlook
    • 21.19.3. Product summary
    • 21.19.4. Recent developments
  • 21.20. Novartis AG
    • 21.20.1. Company details
    • 21.20.2. Financial outlook
    • 21.20.3. Product summary
    • 21.20.4. Recent developments
  • 21.21. Pfizer Inc.
    • 21.21.1. Company details
    • 21.21.2. Financial outlook
    • 21.21.3. Product summary
    • 21.21.4. Recent developments
  • 21.22. Sumitomo Dainippon Pharma Co.,
    • 21.22.1. Company details
    • 21.22.2. Financial outlook
    • 21.22.3. Product summary
    • 21.22.4. Recent developments
  • 21.23. Takeda Pharmaceutical Company Limited
    • 21.23.1. Company details
    • 21.23.2. Financial outlook
    • 21.23.3. Product summary
    • 21.23.4. Recent developments
  • 21.24. Others

22. List of Abbreviations

23. Reference Links

24. Conclusion

25. Research Scope